Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

MDxHealth nieuws 2013

774 Posts
Pagina: «« 1 2 3 4 5 6 ... 39 »» | Laatste | Omlaag ↓
  1. Nel 3 maart 2013 13:46

    • Nel

      Lid sinds: 04 apr 2004

      Laatste bezoek: 04 feb 2025

    • Aanbevelingen

      Ontvangen: 1416

      Gegeven: 219

    •    Aantal posts: 27.770

    quote:

    effegenoeg schreef op 28 februari 2013 14:56:

    Waar is Nel trouwens?
    Waarschijnlijk op zoek naar nieuwe parels...
    Hahaha was vorig jaar er al uit ,maar blijft een aandeel met een alert.
    Nieuwe parels,tja nedsense heeft met Loft een goud product,net zoals hier gaan de kosten voor de baten uit.
    Nedsense heeft nu 3 jaar in loft gestoken en vanaf nu moeten de baten binnen komen.
    Hier geldt het zelfde verhaal,2013 zal het netwerk in de VS worden uitgebreid om vanaf 2014 eindelijk eens tekunnen oosten.
    Exact milestone kan er nog komen en zal uitgifte extra aandelen voorkomen.

    Zijn beide aandelen voor de lange adem

    Succes
  2. Superdude 6 maart 2013 11:51

    • Superdude

      Lid sinds: 09 nov 2011

      Laatste bezoek: 07 mrt 2025

    • Aanbevelingen

      Ontvangen: 101

      Gegeven: 4

    •    Aantal posts: 1.126

    Shareholder Newsletter van deze morgen:

    Welcome to the first MDxHealth newsletter for 2013. We have made a solid start to the year and have laid firm foundations for continued growth throughout the year.

    Our fiscal year 2012 results, issued at the end of February, demonstrated again significant year over year revenue growth, attributable to both ClinicalMDx and PharmacoMDx products and services. In 2012, our revenue increased by 71% to more than €4.6 million in 2012, over 2011.

    For a life science company, it is vital that research is supported by strong, peer-reviewed data. So it was with great pleasure that we announced additional positive data from studies with our ConfirmMDx™ for Prostate Cancer test in February. Clinical validation data from the MATLOC study was published in the current issue of the Journal of Urology, the official journal of the American Urological Society, and two additional scientific abstracts on the test were presented at the prestigious cancer symposium, American Society of Clinical Oncology for Genitourinary Cancers.

    In addition, a pivotal health economics study for the ConfirmMDx for Prostate Cancer test was published in the American Health & Drug Benefits journal in February. This budget impact analysis demonstrates achievable cost savings using the test, which aids urologists in the identification of men who may avoid unnecessary repeat prostate biopsies, thereby reducing overall healthcare spending. The positive economic analysis, combined with the supplementary peer-reviewed scientific data, further supports reimbursement from payors and a positive coverage determination with Medicare. These publications are also important tools for MDxHealth sales force. Dr. Wade Aubry one of the co-authors of the budget impact study provides us with some more information about the importance of this publication in the Q&A section below.

    We are looking forward to a successful 2013 and thank you for your continued interest and support in MDxHealth.

    Sincerely,
    Jan Groen
    President & Chief Executive Officer

    In January 2012, our licensing partner Exact Sciences Corp. (Nasdaq: EXAS) announced that it has submitted the second module of its premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its stool-based DNA colorectal cancer screening test, Cologuard™, which leverages an MDxHealth epigenetic biomarker together with MDxHealth's methylation-specific PCR (MSP) platform.

    Wade Aubry, M.D.

    Lead author of the ConfirmMDx Budget Impact Analysis published in American Health & Drug Benefits, Wade Aubry, M.D., is the Senior Medical Director for Quorum Consulting and Associate Clinical Professor of Medicine at the University of California, San Francisco

    How does a health plan use a budget impact analysis?
    A budget impact analysis is useful in assisting policymakers and financial managers to assess the affordability of new diagnostics, therapies or patient care strategies, such as the ConfirmMDx for Prostate Cancer test. Budget impact models (BIM) provide payers with a useful tool for forecasting the potential financial impact and uptake of a new diagnostic and patient care strategy.

    As a medical director what do you typically look for in a budget impact analysis?
    As a former health plan medical director I would give greater consideration to clinical and health economic data, including budget impact models, which have gone through expert review and published in credible peer-reviewed journals. My co-authors are accomplished experts in their respective fields, including urology, health economics, and medical policy development government agencies and commercial health plans. American Health & Drug Benefits is a credible peer-review publication, and the final published paper benefitted from the peer review process.

    What was the impact/outcome of the budget impact analysis in the ConfirmMDx for Prostate Cancer study?
    The BIM for ConfirmMDx demonstrates that a health care plan with 1 million members can achieve a cost savings of $588 per patient managed using ConfirmMDx on histopathologically negative men at risk for prostate cancer. The clinical utility of ConfirmMDx to distinguish men who may forgo a repeat prostate biopsy procedure from men who may be harboring undetected cancer reduces medically unnecessary repeat biopsies, complications associated with this invasive procedure, and the overall costs using conservative payment rates. By today’s standard of care, a large number of men are currently undergoing 2, 3 and even 4 repeat biopsy procedures. Until the emergence of ConfirmMDx, there were few alternatives to repeat biopsies to manage these men with better, less invasive, and less costly care. This BIM by design incorporates conservative costs for a prostate biopsy procedure and yields a cost savings of $530,801 to the plan or return on investment 1 year out.

    How do you see the Budget Impact Analysis for ConfirmMDx for Prostate Cancer being utilized?
    This budget impact analysis for ConfirmMDx is an important and timely contribution to the literature since stakeholders have a common goal: reducing unnecessary and costly healthcare costs without sacrificing appropriate patient care. With the introduction of ConfirmMDx and the publication of our study in a peer-reviewed publication, there is now emerging evidence for alternative and less invasive ways to manage patients at risk of prostate cancer. Payers that have evaluated the scientific evidence for ConfirmMDx may be more open to providing coverage for ConfirmMDx as a result of improved clinical benefit, reduced complications from repeat biopsies, and potential savings. Urologists may also be more open to utilizing this test for their at-risk patients knowing that they are providing improved patient care while reducing medically unnecessary tests and associated costs.

    Based on the savings demonstrated in the ConfirmMDx budget impact model, how do you see this impacting coverage policy for ConfirmMDx?
    A savings of $588 per patient managed with ConfirmMDx would come to my attention, and this would be likely to occur with other medical directors. Typically, health plan medical directors develop coverage policies by conducting a comprehensive evaluation of the entire body of scientific evidence and opinions of key opinion leaders and specialty societies. The diagnostic performance of ConfirmMDx along with its clinical utility and the Budget Impact Model results should provide the impetus for a health plan to consider a review of ConfirmMDx for Prostate Cancer. In the event a health plan does adopt a favorable coverage policy for ConfirmMDx, I would suggest that payers consider educational campaigns to inform urologists of coverage and criteria to augment appropriate use and enhance return on investment from downstream cost savings.

    Jan Groen, CEO of MDxHealth, will be presenting at the following conferences:

    March 16, 2013

    MDxHealth Presents at the FlandersBio Beleggersdag Conference in Ghent, Belgium

    March 19, 2013

    MDxHealth Presents at the KBC Securities Healthcare Conference, Brussels, Belgium

    April 17, 2013

    MDxHealth to present at the BioCapital Europe 2013 Conference in Amsterdam, The Netherlands

    April 23, 2013

    MDxHealth Presents at the Kempen & Co Healthcare / Life Sciences Conference
  5. [verwijderd] 3 juni 2013 10:27

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Published: 08:00 CEST 03-06-2013 /Thomson Reuters /Source: MdxHealth (TM) /XBRU: MDXH /ISIN: BE0003844611

    MDxHealth Epigenetic Marker as Companion Diagnostic for Irinotecan based Therapy in Colorectal Cancer


    Data Presented at ASCO

    IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, June 3, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced data showing that methylation of the Decoy Receptor 1 (DCR1) gene may help guide oncologists in selecting metastatic colorectal cancer (CRC) patients to receive irinotecan­based therapy. The data, presented on June 2nd at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, showed that CRC patients with methylated DCR1 did not benefit from the addition of irinotecan to capecitabine therapy.



    Identification of DCR1 as a novel hypermethylated gene associated with a lack of benefit in adding irinotecan to capecitabine when treating metastatic colorectal cancer was performed in the pathology department of Prof. Gerrit Meijer (VUmc, Amsterdam) as part of the CTMM public-private partnership DeCoDe (Decrease Colorectal Cancer Death) project. Commenting on the discovery, Prof. Gerrit Meijer said "As part of a concerted effort to reduce the enormous impact of colorectal cancer on patients and healthcare systems, all 14 partners in the DeCoDe project have worked tirelessly to identify novel biomarkers that will aid in the diagnosis and treatment of the disease."

    Prof. Wim Van Criekinge, CSO at MDxHealth added, "Predictive molecular biomarkers can help guide the selection of patients that are likely to respond to a given treatment, or in the case of DCR1, identify patients who are unlikely to respond to specific therapy, potentially sparing unnecessary toxicity and allowing treatment with more effective, alternative therapies earlier."

    "The innovative use of advanced bioinformatics, combined with several Next Generation molecular profiling methods, and integrated with pharmacological data is one the key missions of NXTGNT and enables the highly efficient identification of specific predictive biomarkers, such as DCR1," stated Prof. Dieter Deforce, Head of the Laboratory of Pharmaceutical Biotechnology at NXTGNT Center in Pharmaco (Epi)genomics, a joint collaboration between MDxHealth and the Ghent University.

    Study Details

    The presence of DNA methylation for a selected panel of 22 genes was assessed on primary tumors of 185 patients with metastatic CRC treated with first­line capecitabine (CAP, n=90) or a combination of capecitabine and irinotecan (CAPIRI, n=95) in the phase 3 CAIRO trial. Methylation status of each gene was correlated to progression free survival (PFS) by treatment regimen. Genes for which methylation status was associated with response to irinotecan were validated in 166 patients treated with first­line CAP (n=78) or CAPIRI (n=88). In CAPIRI treated patients, DCR1 methylation was correlated to a shorter PFS compared to patients with unmethylated DCR1 (hazard ratio [HR]=0.4, p = 0.0009). In patients with methylated DCR1 PFS did not improve with CAPIRI treatment, compared to treatment with CAP (discovery set: HR=0.8 p=0.4; validation set: HR=1.1, p=0.6, in contrast to patients with unmethylated DCR1 (discovery set: HR=2.5, p=0.00004; validation set: HR=1.7, p=0.004).


    About CTMM

    The CTMM (Center for Translational Molecular Medicine) is a Netherlands-based public-private partnership. It is dedicated to the development of technologies in molecular medicine that enable early diagnosis and personalized treatment for main areas of disease causing mortality and diminished quality of life in the western world. Focus lies on oncology, cardiovascular, neurodegenerative and infectious/auto-immune disease. CTMM operates by inviting, assessing, and funding multidisciplinary projects that involve active participation by Netherlands-based academia and industry. All CTMM projects are judged by an independent International Advisory Board and approved by a Supervisory Board based on their significant potential to translate research knowledge into clinical practice. The CTMM is funded by the Dutch government (50%), academia (25%) and industry (25%). Additional funding is provided by supporting foundations on behalf of patients.

    DeCoDe (Decrease Colorectal Cancer Death) is one of the CTMM projects, with 14 partners and a project budget of 18.6 M Euro. Key figures CTMM: 119 partners, M€ 302.7 allocated budget until the end of 2015, 22 projects/consortia, www.ctmm.nl.



    About MDxHealth®

    MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDxTM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain, lung and colon cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth's website at www.mdxhealth.com.
  7. [verwijderd] 18 juni 2013 08:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Rudi Pauwels wordt bestuurder bij MDxHealth
    18-06-2013 08:32:09
    Rudi Pauwels, een van de grootste namen uit de Belgische biotechsector en oprichter van onder andere Biocartis, wordt bestuurder bij het Luikse diagnosticabedrijf MDxHealth.

    Pauwels wordt wel eens de Midas van de biotechsector genoemd. Alles wat hij in handen krijgt, verandert in goud. Hij lag aan de basis van Galapagos, dat intussen ruim 400 miljoen euro waard is op de Brusselse beurs. Hij was de oprichter van Tibotec-Virco, de pionier in aidsmedicijnen die in de nasleep van 9/11 voor 320 miljoen dollar werd overgenomen door Johnson & Johnson.

    Met Biocartis, dat hij in 2007 oprichtte, haalde hij al 125 miljoen euro op. Het bedrijf lanceerde onlangs een eerste product. De technologie van Biocartis werd ook door het World Economic Forum erkend als revolutionair en disruptief. Het WEF riep Biocartis uit tot een van de 25 technologiepioniers van 2012. Daarmee vertoeft het biotechnologiebedrijf in het gezelschap van bedrijven als Twitter en Spotify.

    MDxHealth is op de Brusselse beurs 52,6 miljoen euro waard.

  8. [verwijderd] 19 juni 2013 13:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Binck stopt morgen met de oude website. Jammer, want via de nieuwe sites wordt geen nieuws verstrekt over MDxH, Thrombo, UCB, GIMV, etc.
    Ik heb mijn beklag al gedaan. Wie volgt?
  9. [verwijderd] 21 juni 2013 10:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik heb ook een bericht gestuurd aan Binck. Hopelijk doen ze er wat mee.

    Verder hoop ik de komende tijd een leuke stijging hier te zien, aangezien we een beetje blijven hangen tussen de 2,05 en de 2,10
  10. Cu Chulainn 25 juni 2013 18:16

    • Cu Chulainn

      Lid sinds: 21 sep 2009

      Laatste bezoek: 24 jun 2024

    • Aanbevelingen

      Ontvangen: 34

      Gegeven: 28

    •    Aantal posts: 483

    MDxHealth Completes €18 Million ($24M) Equity Raise



    LIEGE, BELGIUM - June 25, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, announced today that it successfully raised an aggregate amount of €18 million in a private placement through the issuance of 8,737,683 new shares at a subscription price of EUR 2.06 per share (which represents the average closing price of the company's shares during the 30 preceding calendar days). Certain funds managed by Valiance Asset Management Ltd participated in the private placement for a total amount of 4,368,932 new shares and Biovest Comm. VA, the investment company of Rudi Mariën, participated in the private placement for a total amount of 2,427,184 new shares. The remaining 1,941,747 new shares were underwritten by Petercam who acted as sole lead manager in the transaction, and will be placed with a limited group of investors.

    The net proceeds of the private placement will be used to support and scale-up the Company's U.S.-based CLIA-registered commercial laboratory, its US-based sales and marketing efforts, European and global commercial efforts for its Clinical Molecular Diagnostics (ClinicalMDx) and Pharmaco Molecular Diagnostics (PharmacoMDx) solutions and services to clinicians and pharmaceutical customers, and to accelerate proprietary product development.



    The 1,941,747 new shares underwritten by Petercam with the view to be placed with investors are expected to be admitted to listing on NYSE Euronext Brussels immediately following their issuance. The other new shares are expected to be listed in the near future following the approval and publication of a listing prospectus.



    "This financing marks a major milestone in the growth and success of our Company," stated Dr. Jan Groen, CEO of MDxHealth. "In response to the increasing demand for our ConfirmMDxTM for Prostate Cancer test in the U.S., we will expand our commercial efforts by investing in personnel and infrastructure to ensure we are well positioned for new tests emerging from our product pipeline. We will also use proceeds to further emphasize our global commercialization efforts, offering our cutting edge products and services to clinical and pharmaceutical customers, with the goal of accelerating and diversifying our revenue base."



    About MDxHealth®

    MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The Company's first commercial product, ConfirmMDxTM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth's website at www.mdxhealth.com.
  11. [verwijderd] 29 juli 2013 08:50

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Press Release
    MDxHealth and Bostwick Laboratories Announce Marketing Agreement for ConfirmMDx(TM) for Prostate Cancer

    IRVINE, CA, UNIONDALE, NY and LIEGE, BELGIUM - 8:00 AM CET, July 29, 2013 - MDxHealth SA (NYSE Euronext: MDXH) and Bostwick Laboratories, Inc. today announced that they have entered into a marketing agreement to commercialize MDxHealth's ConfirmMDx for Prostate Cancer test. Bostwick Laboratories is a national, full-service laboratory specializing in anatomic and clinical pathology, with a focus on uropathology. The agreement provides MDxHealth with access to one of the largest urology networks in the United States.
    "We are excited to partner with Bostwick Laboratories, a recognized leader in urologic anatomic pathology services with a focus on improving patient care and outcomes. This marketing agreement provides their extensive customer base with access to our ConfirmMDx for Prostate Cancer test" said Dr. Jan Groen, CEO of MDxHealth. "With their national reach and strong reputation, Bostwick Laboratories is an ideal partner to help us continue building upon the momentum we have achieved to date, raising awareness and access to ConfirmMDx within the urology community."
    "We are pleased to announce our partnership with MDxHealth and the addition of ConfirmMDx for Prostate Cancer to our portfolio of testing services. This epigenetic test provides additional clinical utility for our urology clients and their patients," stated Martin Stefanelli, CEO of Bostwick Laboratories. "We are committed to consistently providing new testing that enhances patient care and helps physicians make better treatment decisions and we believe the ConfirmMDx test delivers on that promise."
    About ConfirmMDx for Prostate Cancer
    Over 975,000 American men receive a negative prostate biopsy result each year, though approximately 25% of these men may still harbor occult prostate cancer. This well-documented risk of undetected cancer, often with clinically significant Gleason scores, leads to a high rate of repeat biopsies with greater than 40% of men receiving at least one repeat biopsy, and many receiving a 3rd and 4th biopsy. Today's gold standard diagnostic approach is the prostate biopsy procedure, collecting 10-12 needle core biopsy samples; however this sampling represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level. This molecular "halo" around a cancer lesion can be present despite having a normal appearance under the microscope. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and rule in high-risk patients who may require repeat biopsies and potential treatment.
    About Bostwick Laboratories
    Bostwick Laboratories provides anatomic and clinical pathology laboratory services specializing in the monitoring and diagnosis of cancer. Bostwick Laboratories is a leader in urologic pathology with expertise and a growing presence in the women's health, dermatology, gastroenterology, nephrology and hematology sectors of the anatomic pathology market. Bostwick Laboratories and its staff of board-certified, internationally recognized pathologists provide definitive diagnoses and the most technologically advanced testing available to help physicians and patients choose the best course of treatment. For more information, visit our website at www.bostwicklaboratories.com.
    About MDxHealth
    MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. By applying patented DNA methylation platform and biomarkers, MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. For more information visit www.mdxhealth.com.
    For more information:
    Dr. Jan Groen, CEO Mike Sinclair Matt Clawson
    MDxHealth Halsin Partners Allen & Caron, Inc
    US: +1 949 812 6979 UK: +44 20 7318 2955 US: +1 949 474 4300
    BE: +32 4 364 20 70 Cell: +44 7968 022075 matt@allencaron.com
    info@mdxhealth.com msinclair@halsin.com


    Brent Sower
    Vice President of Marketing
    Bostwick Laboratories
    US: +1 804 967 9225
    Cell: +1 804 387 2064
    bdsower@bostwicklaboratories.com
    This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.



    NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

    English version
  12. Binckie 123 29 juli 2013 12:41

    • Binckie 123

      Lid sinds: 16 nov 2006

      Laatste bezoek: 09 nov 2022

    • Aanbevelingen

      Ontvangen: 22

      Gegeven: 0

    •    Aantal posts: 93

    Mooi, heel mooi!
    Een verdere onderbouwing voor de positieve halfjaarresultaten van 22 augustus a.s.
    Ook zal een meer dan uitstekende outlook de koers flink opstuwen.
    Bijkopen is het motto !!!
  13. [verwijderd] 1 augustus 2013 09:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    E. David Crawford, MD: The Benefits of ConfirmMDx

    May 24, 2013
    E. David Crawford, MD, head of urologic oncology and a professor at the University of Colorado School of Medicine in Denver spoke with Renal & Urology News about the benefits of a new method that could potentially limit the number of unnecessary repeat biopsies.

    www.renalandurologynews.com/e-david-c...
  14. [verwijderd] 2 augustus 2013 11:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik vind dat het ondanks al het goede nieuws van MDxHealth erg stil is met de aandelen. Er gebeurt al dagen niets.

    Wat zou hier achter kunnen zitten? Of is het gewoon de vakantieperiode en zijn de mensen die normaal voor koersschommelingen zorgen even weg?
  15. [verwijderd] 5 augustus 2013 15:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    cyborg1298 schreef op 2 augustus 2013 11:07:

    Ik vind dat het ondanks al het goede nieuws van MDxHealth erg stil is met de aandelen. Er gebeurt al dagen niets.

    Wat zou hier achter kunnen zitten? Of is het gewoon de vakantieperiode en zijn de mensen die normaal voor koersschommelingen zorgen even weg?
    Wachten tot de doorbraakzone van 2,52 doorbroken wordt, we zijn met 2,49 heel dichtbij en zal binnen enkele dagen weleens kunnen spiken naar 2,75-3,00 euro. Zelf weer een mooie positie van 41000 stukjes genomen. Bij definitieve doorbraak koop ik nog een mooie set bij. Vandaag is het event waar mdxhealth zal presenteren, wellicht morgen flink wat actie mbt tot wat positieve ontwikkelingen.

    Mvg,

    DoC.
  17. [verwijderd] 5 augustus 2013 19:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Debit or Credit schreef op 5 augustus 2013 15:12:

    [...]

    Wachten tot de doorbraakzone van 2,52 doorbroken wordt, we zijn met 2,49 heel dichtbij en zal binnen enkele dagen weleens kunnen spiken naar 2,75-3,00 euro. Zelf weer een mooie positie van 41000 stukjes genomen. Bij definitieve doorbraak koop ik nog een mooie set bij. Vandaag is het event waar mdxhealth zal presenteren, wellicht morgen flink wat actie mbt tot wat positieve ontwikkelingen.

    Mvg,

    DoC.
    Bij Archos is er ook wat aan de hand, woensdag cijfers.
774 Posts
Pagina: «« 1 2 3 4 5 6 ... 39 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.097
AB InBev 2 5.525
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.862
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.770
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.764
Aedifica 3 923
Aegon 3.258 322.957
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.896
Agfa-Gevaert 14 2.051
Ahold 3.538 74.343
Air France - KLM 1.025 35.219
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.046
Alfen 16 25.012
Allfunds Group 4 1.510
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.502
AMG 971 134.000
AMS 3 73
Amsterdam Commodities 305 6.734
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.027
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.787
Arcelor Mittal 2.034 320.848
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.332
Aroundtown SA 1 220
Arrowhead Research 5 9.747
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.443
ASML 1.766 108.719
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 521
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.690
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.410